Nöromusküler Hastalıklarda Genetik Yaklaşım ve Genetik Testlerin Tanısal Kullanımı
Özet
Kalıtsal nöromüsküler hastalıkların tanısında altın standart olan genetik analizler, klinik fenotiplerin belirlenmesinde ve kesin tanı koyma sürecinde kritik bir rol oynamaktadır. Gelişen moleküler teknolojiler, özellikle SMA ve DMD gibi bozukluklarda invaziv yöntemlere olan ihtiyacı azaltarak daha hızlı ve ekonomik bir tanısal yaklaşım sunmaktadır. Buna karşın, LGMD ve CMT gibi karmaşık tablolarda tanısal zorluklar devam etmekte olup, klinisyenlerin güncel teknolojileri sürekli takibi ve hasta psikolojisini gözeten genetik danışmanlık süreçleri zorunludur.
Genetic analysis stands as the gold standard for diagnosing hereditary neuromuscular diseases, playing a critical role in identifying clinical phenotypes and establishing definitive diagnoses. Advancing molecular technologies offer a faster and more cost-effective diagnostic approach, particularly in conditions like SMA and DMD, by reducing the reliance on invasive procedures such as muscle biopsies. Despite these advancements, diagnostic challenges persist in complex cases like LGMD and CMT, necessitating clinicians' continuous adaptation to new technologies and the integration of genetic counseling to address patient psychological and familial implications.
Referanslar
Mah JK, Korngut L, Fiest KM, et al. A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies. Can J Neurol Sci 2016;43:163-77.
Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord 1991;1:19-29.
Bhatt JM. The Epidemiology of Neuromuscular Diseases. Neurol Clin 2016;34:999-1021.
Ramelli GP, Herrmann U, Lutschg J. [A clinical approach in neuromuscular diseases in childhood]. Praxis (Bern 1994) 2010;99:785-92.
Moss KR, Bopp TS, Johnson AE, Hoke A. New evidence for secondary axonal degeneration in demyelinating neuropathies. Neurosci Lett 2021;744:135595.
Greenberg SA, Walsh RJ. Molecular diagnosis of inheritable neuromuscular disorders. Part II: Application of genetic testing in neuromuscular disease. Muscle Nerve 2005;31:431-51.
Flusser H, Halperin D, Kadir R, Shorer Z, Shelef I, Birk OS. Novel SBF1 splice-site null mutation broadens the clinical spectrum of Charcot-Marie-Tooth type 4B3 disease. Clin Genet 2018;94:473-9.
Fardeau M, Desguerre I. Diagnostic workup for neuromuscular diseases. Handb Clin Neurol 2013;113:1291-7.
Arnold WD, Flanigan KM. A practical approach to molecular diagnostic testing in neuromuscular diseases. Phys Med Rehabil Clin N Am 2012;23:589-608.
2nd Workshop of the European CMT Consortium: 53rd ENMC International Workshop on Classification and Diagnostic Guidelines for Charcot-Marie-Tooth Type 2 (CMT2-HMSN II) and Distal Hereditary Motor Neuropathy (distal HMN-Spinal CMT) 26-28 September 1997, Naarden, The Netherlands. Neuromuscul Disord 1998;8:426-31.
Klein CJ. Charcot-Marie-Tooth Disease and Other Hereditary Neuropathies. Continuum (Minneap Minn) 2020;26:1224-56.
Weis J, Senderek J. Introduction to the hereditary neuropathies. New York: Wiley; 2014.
Rudnik-Schoneborn S, Tolle D, Senderek J, et al. Diagnostic algorithms in Charcot-Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patients. Clin Genet 2016;89:34-43.
England JD, Gronseth GS, Franklin G, et al. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R 2009;1:5-13.
Gess B, Schirmacher A, Boentert M, Young P. Charcot-Marie-Tooth disease: frequency of genetic subtypes in a German neuromuscular center population. Neuromuscul Disord 2013;23:647-51.
Bansagi B, Griffin H, Whittaker RG, et al. Genetic heterogeneity of motor neuropathies. Neurology 2017;88:1226-34.
Previtali SC, Zhao E, Lazarevic D, et al. Expanding the spectrum of genes responsible for hereditary motor neuropathies. J Neurol Neurosurg Psychiatry 2019;90:1171-9.
Liu X, Duan X, Zhang Y, Sun A, Fan D. Molecular analysis and clinical diversity of distal hereditary motor neuropathy. Eur J Neurol 2020;27:1319-26.
Hannibal MC, Ruzzo EK, Miller LR, et al. SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophy. Neurology 2009;72:1755-9.
Morales JA, Mahajan K. Dystrophinopathies. StatPearls. Treasure Island (FL)2021.
Perry MM, Muntoni F. Noncoding RNAs and Duchenne muscular dystrophy. Epigenomics 2016;8:1527-37.
Hathout Y, Seol H, Han MH, Zhang A, Brown KJ, Hoffman EP. Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Clin Proteomics 2016;13:9.
Forbes SC, Walter GA, Rooney WD, et al. Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology 2013;269:198-207.
Kim HK, Serai S, Lindquist D, et al. Quantitative Skeletal Muscle MRI: Part 2, MR Spectroscopy and T2 Relaxation Time Mapping-Comparison Between Boys With Duchenne Muscular Dystrophy and Healthy Boys. AJR Am J Roentgenol 2015;205:W216-23.
Domingos J, Sarkozy A, Scoto M, Muntoni F. Dystrophinopathies and Limb-Girdle Muscular Dystrophies. Neuropediatrics 2017;48:262-72.
Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews((R)). Seattle (WA)1993.
Dent KM, Dunn DM, von Niederhausern AC, et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 2005;134:295-8.
Prior TW, Bridgeman SJ. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. J Mol Diagn 2005;7:317-26.
Flanigan KM, Dunn DM, von Niederhausern A, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009;30:1657-66.
Flanigan KM, Dunn DM, von Niederhausern A, et al. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat 2011;32:299-308.
Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet 2003;72:931-9.
Joncourt F, Neuhaus B, Jostarndt-Foegen K, Kleinle S, Steiner B, Gallati S. Rapid identification of female carriers of DMD/BMD by quantitative real-time PCR. Hum Mutat 2004;23:385-91.
Bird TD. Myotonic Dystrophy Type 1. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews((R)). Seattle (WA)1993.
Datta N, Ghosh PS. Update on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers. Curr Neurol Neurosci Rep 2020;20:14.
Magri F, Nigro V, Angelini C, et al. The italian limb girdle muscular dystrophy registry: Relative frequency, clinical features, and differential diagnosis. Muscle Nerve 2017;55:55-68.
Thompson R, Straub V. Limb-girdle muscular dystrophies - international collaborations for translational research. Nat Rev Neurol 2016;12:294-309.
Piluso G, Dionisi M, Del Vecchio Blanco F, et al. Motor chip: a comparative genomic hybridization microarray for copy-number mutations in 245 neuromuscular disorders. Clin Chem 2011;57:1584-96.
de Greef JC, Lemmers RJ, Camano P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010;75:1548-54.
Preston MK, Tawil R, Wang LH. Facioscapulohumeral Muscular Dystrophy. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews((R)). Seattle (WA)1993.
Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010;329:1650-3.
Brais B, Xie YG, Sanson M, et al. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet 1995;4:429-34.
Trollet C, Boulinguiez A, Roth F, et al. Oculopharyngeal Muscular Dystrophy. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews((R)). Seattle (WA)1993.
Menezes MP, Waddell LB, Evesson FJ, et al. Importance and challenge of making an early diagnosis in LMNA-related muscular dystrophy. Neurology 2012;78:1258-63.
Bialer MG, Bruns DE, Kelly TE. Muscle enzymes and isoenzymes in Emery-Dreifuss muscular dystrophy. Clin Chem 1990;36:427-30.
Gueneau L, Bertrand AT, Jais JP, et al. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2009;85:338-53.
Nallamilli BRR, Chakravorty S, Kesari A, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol 2018;5:1574-87.
Park J, Oh HM, Park HJ, et al. Usefulness of comprehensive targeted multigene panel sequencing for neuromuscular disorders in Korean patients. Mol Genet Genomic Med 2019;7:e00947.
Ankala A, da Silva C, Gualandi F, et al. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. Ann Neurol 2015;77:206-14.
Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol 2011;68:979-84.
Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews((R)). Seattle (WA)1993.
Serra-Juhe C, Tizzano EF. Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors. Eur J Hum Genet 2019;27:1774-82.
Kuhlenbaumer G, Kress W, Ringelstein EB, Stogbauer F. Thirty-seven CAG repeats in the androgen receptor gene in two healthy individuals. J Neurol 2001;248:23-6.
Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord 2012;22:99-111.
